Q-omics provides the consensus-scored MIR1226 profile across patient tissues and cancer cell-line models. MIR1226 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR1226 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, MIR1226 RNA expression shows 2,581 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight BLCA, and LUSC as cancer lineages where MIR1226 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1226 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1226 survival associations across molecular data types. MIR1226 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1226 RNA expression–survival associations across cancer types. High MIR1226 expression shows unfavorable associations in READ, SKCM, MESO, ACC and CESC, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR1226 RNA expression.
This table summarizes MIR1226 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1226. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1226 shows lower tumor expression in LUSC. The LUSC box plot shows higher MIR1226 RNA expression in normal versus tumor tissue (log2 FC = −0.120, t-test p = .008).
This table shows molecular features associated with MIR1226 in patient tissues and cancer cell lines. In patient samples, MIR1226 shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set.
